PPT-Cannabis Concentration and Health Risks

The Role of Potency in Cannabis Use Outcomes A joint report from the University of Washington and Washington State University Workgroup for the Prevention and Research Sub Committee PRSC October 2020. Cannabis contains a number of active substances like dronabinol THC and cannabidiol CBD THC is mainly responsible for the e64256ects of cannabis but others like CBD may also in64258uence the e64256ectiveness of the drug The chemical composition of Dr. Bareket Schiff Keren. Some history. GLOBAL. AND. LOCAL. Gan. -. zi. -gun-nu. – the drug that takes away the mind. Azallu. . – hand of ghost, poison of all limbs. (neurological diseases?). Talking to your doctor, Safety and Update on Clinical Trials. Lubov. . Romantseva. , MD. Child Neurology and Epilepsy. Rush University Medical Center. Nov 12, 2016. Disclosures. I have no financial interest in any pharmaceutical company mentioned in this presentation. Professor Jennifer H. Martin . MBChB. , FRACP, PhD. Chair, Clinical Pharmacology. Uni. of Newcastle, Australia. Overview. Need for evidence . Where there is evidence. Challenges of cannabis research . Presented by: Candice Beathard, PhD. December 15, 2015 . Background. 23 States and D.C. have enacted medical cannabis programs. 1. . 1. Marijuana Policy Project, 2015. . Background. State programs specify list of qualifying conditions. IWK Health Centre, Halifax, Nova Scotia. CSAM-SCAM Fundamentals. DISCLOSURE. No conflict of interest to declare. No pharmaceutical industry support. No support from cannabis producers. Fundamentals: Cannabis Dependence. Erik Messamore, MD, PhD. Associate Professor of Psychiatry, Northeast Ohio Medical University. Medical Director, Best Practices for Schizophrenia Treatment (BeST) Center. Overview. Cannabis association with acute psychosis is well-known. Gregg VandeKieft, MD, MA. WSHPCO “Expanding dimensions in hospice & palliative care”. Chelan, . wa. October 10, 2017. Disclosure. Dr. VandeKieft does not have any conflicts of interest to disclose. He will discuss medical applications of cannabis, but will not discuss off-label use of medications.. Chief of Palliative Care. Duke University. Conflicts of interest. SAB: Curio Wellness, Gram Research. Senior advisor: Silver Swan Capital. Principal: Medicinal Management. . No consulting or speaking for the pharmaceutical industry . Victoria. Dr. Daniel Perkins. Manager Research Strategy and Policy. Office of Medicinal Cannabis. Department of Health and Human Services Victoria. Cannabis regulatory framework. Victorian reform. December . Dr. Robert Strang, CMOH. Nova Scotia Department of Health and Wellness . Cannabis . use, lifetime and past year, . by . province, 2013. . Health Canada (2014). Last 12 month use of cannabis, by province, grades . Dr. Nick Salamie PharmD, . RPh. Autoimmune Disorders. Symptoms. Traditional Treatments. NSAIDs. Aleve. Advil. Immunosuppressant Drugs. Corticosteroids. Janus kinase inhibitors. Calcineurin inhibitors. Marinol and . Syndros. (synthetic THC Max daily 20mg/16.8mg) and . Cesamet. (THC analog) - anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS), nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. . world. Tania Ramírez. Map of countries in which medicinal cannabis is available. Medicinal cannabis . regulated. Argentina, Australia, Brazil, Canada, Chile, Colombia, Croatia, Czech Republic, Finland, France, Germany, Greece, Israel, Italy,...